Norway - Norwegian - Statens legemiddelverk

orifarm as - zolmitriptan - smeltetablett - 2.5 mg

Norway - Norwegian - Statens legemiddelverk

amdipharm ltd - lanreotidacetat - injeksjonsvæske, oppløsning i ferdigfylt sprøyte - 90 mg

Norway - Norwegian - Statens legemiddelverk

amdipharm ltd - lanreotidacetat - injeksjonsvæske, oppløsning i ferdigfylt sprøyte - 60 mg

Norway - Norwegian - Statens legemiddelverk

amdipharm ltd - lanreotidacetat - injeksjonsvæske, oppløsning i ferdigfylt sprøyte - 120 mg

European Union - Norwegian - EMA (European Medicines Agency)

eli lilly nederland b.v. - tadalafil - hypertensjon, pulmonal - urologika - adultstreatment of pulmonary arterial hypertension (pah) classified as who functional class ii and iii, to improve exercise capacity (see section 5. effekt har blitt vist i idiopatisk pah (ipah) og i pah relatert til kollagenvaskulær sykdom. paediatric populationtreatment of paediatric patients aged 2 years and above with pulmonary arterial hypertension (pah) classified as who functional class ii and iii.

European Union - Norwegian - EMA (European Medicines Agency)

bayer ag - riociguat - hypertensjon, pulmonal - antihypertensive midler for pulmonal arteriell hypertensjon - chronic thromboembolic pulmonary hypertension (cteph)adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah)adultsadempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. effekten har vært vist i en pah befolkningen, herunder aetiologies av idiopatisk eller heritable pah eller pah assosiert med bindevev sykdom. paediatricsadempas is indicated for the treatment of pah in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with who functional class (fc) ii to iii in combination with endothelin receptor antagonists.

Norway - Norwegian - Statens legemiddelverk

accord healthcare b.v. - solifenacinsuksinat - tablett, filmdrasjert - 5 mg

Norway - Norwegian - Statens legemiddelverk

accord healthcare b.v. - solifenacinsuksinat - tablett, filmdrasjert - 10 mg

European Union - Norwegian - EMA (European Medicines Agency)

acino ag - klopidogrel - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - antithrombotic agents - clopidogrel is indicated in adults for the prevention of atherothrombotic events in: , , , patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease, non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa), st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy, patients suffering from acute coronary syndrome. , ,.